One-third of target group now vaccinated against monkeypox 10,440 monkeypox vaccinations have already been administered in the Netherlands in the last few weeks. That represents about one-third of the target group currently eligible to get the vaccine against monkeypox. Science Photo Library / ANP
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
WHO Chemical Risk Assessment Workshop on new and emerging risks to human health from chemicals RIVM is hosting an international workshop on new and emerging risks from chemicals on 20 and 21 February 2019.
Possible health risks due to exposure to chromium-6 at tROM project Tilburg Research by RIVM shows that the participants in the so-called tROM project, their supervisors and other people involved may have been exposed to chromium-6.
Kick off European Project VITAL: Vaccines and InfecTious diseases in the Ageing popuLation Recently, the EU-sponsored Vaccines and InfecTious diseases in the Ageing popuLation (VITAL) project was launched.
Citizen Science Magazine; everyone's a scientist “RIVM is committed to being innovative, and becoming a key player in citizen science is fully in line with that goal,” says Danielle Timmermans, Chief Science Officer for Risk Communication at RIVM
Framework Agreement signed between INERIS and RIVM to strengthen cooperation On 7 November 2018, Raymond Cointe, Director-General of INERIS and Hans Brug, Director-General of RIVM, signed a Framework Agreement. RIVM has been working with the French National Institute f